HOME >> BIOLOGY >> NEWS
Study: 'Pill' may cancel some bone-building benefits of exercise

WEST LAFAYETTE, Ind. Young women who take oral contraceptives and exercise may have increased risks of bone loss, according to recent research at Purdue University.

A two-year study headed by Connie Weaver, head and distinguished professor of foods and nutrition, suggests women ages 18 to 30 who exercise while using oral contraceptives may lose bone density in the hip and spine, even more than women who take the pill and are sedentary. This loss of density could make a women susceptible to bone fractures later in life.

However, the study also indicates that women in this group who get the minimum daily requirements for calcium may be able to ward off bone loss.

"The study showed that, overall, exercise had positive affects on whole body bone mineral content for everyone," Weaver says. "Only the spine and hip were compromised if subjects who were on oral contraceptives exercised, and only then if calcium intakes were inadequate."

The purpose of the study, funded through the National Institutes of Health, was to investigate the effects of exercise on bone mineral content and bone mineral density in women 18 to 30 years old who either were or were not taking birth control pills. The study started with 180 women. At the end of the two-year period, 55 women remained.

The study, published in the June issue of the scientific journal Medicine and Science in Sports and Exercise, had several unexpected results, Weaver says.

One big surprise was that for women who use birth control pills, exercise had a negative impact on the spine and the hip, especially in the first six months, she says. By the end of the two years, that group fell below the groups of non-exercisers or non-pill users in terms of bone mineral content and bone mineral density.

Bone mineral content and bone mineral density are both indicators of bone mass. It is widely held that women with higher bone mass early in adulthood are at a lower risk for developing osteoporos
'"/>

Contact: Susan Gaidos
sgaidos@purdue.edu
765-494-2081
Purdue University
20-Jun-2001


Page: 1 2 3 4

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study: A little help from friends makes wounds heal faster
3. Study: Mothers turn fearless when peptide level drops
4. Study: Artificial sweetener may disrupt bodys ability to count calories
5. Study: Mimicking viruses may provide new way to defeat them
6. Study: Stroke victims may retain continuous motion ability
7. Study: Adults maintain significant improvement in ADHD with long-term use of amphetamine
8. Study: Prenatal screening in Haiti region cut syphilis by 75 percent
9. Study: Isoflavone-enriched soy proteins fail to increase bone mineral density in young women
10. Study: Genome-wide scanning unravels complex birth defect
11. Study: Higher energy intake, obesity affects all age groups, not just youths

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Pill may cancel some bone building benefits exercise

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: